Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Molecular basis for the disease-modifying effects of belimumab in systemic lupus erythematosus and molecular predictors of early response: blood transcriptome analysis implicates the innate immunity and DNA damage response pathways.
Moysidou GS, Garantziotis P, Sentis G, Nikoleri D, Malissovas N, Nikoloudaki M, Stergioti EM, Polia S, Paschalidis N, Filia A, Grigoriou M, Nikolopoulos D, Kapsala N, Katechis S, Fanouriakis A, Bertsias G, Boumpas DT. Moysidou GS, et al. Among authors: garantziotis p. Ann Rheum Dis. 2024 Nov 13:ard-2024-226051. doi: 10.1136/ard-2024-226051. Online ahead of print. Ann Rheum Dis. 2024. PMID: 39510807 Free article.
Disentangling the riddle of systemic lupus erythematosus with antiphospholipid syndrome: blood transcriptome analysis reveals a less-pronounced IFN-signature and distinct molecular profiles in venous versus arterial events.
Nikolopoulos D, Loukogiannaki C, Sentis G, Garantziotis P, Manolakou T, Kapsala N, Nikoloudaki M, Pieta A, Flouda S, Parodis I, Bertsias G, Fanouriakis A, Filia A, Boumpas DT. Nikolopoulos D, et al. Among authors: garantziotis p. Ann Rheum Dis. 2024 Aug 27;83(9):1132-1143. doi: 10.1136/ard-2024-225664. Ann Rheum Dis. 2024. PMID: 38609158 Free PMC article.
Pragmatic targets for moderate/severe SLE and their implications for clinical care and trial design: sustained DORIS or LLDAS for at least 6 months is sufficient while their attainment for at least 24 months ensures high specificity for damage-free progression.
Pitsigavdaki S, Nikoloudaki M, Garantziotis P, Silvagni E, Repa A, Marangoni A, Flouri I, Avgoustidis N, Parperis K, Fanouriakis A, Govoni M, Sidiropoulos P, Boumpas DT, Bortoluzzi A, Bertsias G. Pitsigavdaki S, et al. Among authors: garantziotis p. Ann Rheum Dis. 2024 Mar 12;83(4):464-474. doi: 10.1136/ard-2023-224919. Ann Rheum Dis. 2024. PMID: 38233103 Free PMC article.
The genomic landscape of ANCA-associated vasculitis: Distinct transcriptional signatures, molecular endotypes and comparison with systemic lupus erythematosus.
Banos A, Thomas K, Garantziotis P, Filia A, Malissovas N, Pieta A, Nikolakis D, Panagiotopoulos AG, Chalkia A, Petras D, Bertsias G, Boumpas DT, Vassilopoulos D. Banos A, et al. Among authors: garantziotis p. Front Immunol. 2023 Mar 27;14:1072598. doi: 10.3389/fimmu.2023.1072598. eCollection 2023. Front Immunol. 2023. PMID: 37051253 Free PMC article.
Cross-species transcriptome analysis for early detection and specific therapeutic targeting of human lupus nephritis.
Frangou E, Garantziotis P, Grigoriou M, Banos A, Nikolopoulos D, Pieta A, Doumas SA, Fanouriakis A, Hatzioannou A, Manolakou T, Alissafi T, Verginis P, Athanasiadis E, Dermitzakis E, Bertsias G, Filia A, Boumpas DT. Frangou E, et al. Among authors: garantziotis p. Ann Rheum Dis. 2022 Oct;81(10):1409-1419. doi: 10.1136/annrheumdis-2021-222069. Epub 2022 Jul 29. Ann Rheum Dis. 2022. PMID: 35906002 Free PMC article.
19 results